Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (APS) is all set.
The Canadian MDXX class molecules company, together with Australian partner digital healthcare firm Vitura Health Ltd., announced the new business’ launch in May, some months prior to the country beginning the implementation of legal psychedelic-assisted therapies prescription, by authorized physicians, for patients with PTSD and Major Depressive Disorder -the first country in the world to legalize such treatment options.
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.